Comments
Dr Reddy’s Laboratories Ltd has launched Icosapent Ethyl capsules in the US market after approval from the US Food and Drug Administration (US FDA).
Dr Reddy’s Icosapent Ethyl Capsules, 1 gram is approved to be used as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia.
Also read: Dr Reddy’s in last leg of pilot launch of SputnikV vaccine
“However, it is not approved to be used as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularisation, and unstable angina requiring hospitalisation in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease,'' the Hyderabad-based company said in a release.
The effect of Icosapent Ethyl Capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined, it added.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.